PMID: 11328911May 1, 2001Paper

An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
D PolskyK A Schulman

Abstract

Immunosuppressive therapy with cyclosporin A has substantially improved clinical outcomes for renal transplantation. Whether basiliximab (a chimeric monoclonal antibody) demonstrates economic and quality-of-life advantages over other induction therapies has not yet been shown. A multi-centre open-label clinical trial was conducted among renal transplant recipients in the US, in which patients were randomized into two induction therapy regimens: basiliximab and antithymocyte globulin (ATG) as part of a quadruple immunosuppressive regimen. Medical resources used and a EuroQol visual analogue scale (VAS) rating of quality of life were collected prospectively for the 135 dosed subjects for a period of 1 year post-treatment. We analysed the differences between treatment groups in 1-year costs and 1-year quality-adjusted survival. We also conducted a post hoc analysis of outcomes among the subgroup of patients identified as high risk. A significant difference was observed in first-year post-treatment costs (basiliximab, $45857; ATG, $54729; difference, $8872 (95% CI, $1169 to $16573). The savings from basiliximab can be attributed to the less expensive induction therapy (basiliximab, $2378; ATG, $8670; difference, $6292 (95% CI, $516...Continue Reading

References

Apr 29, 1998·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·D ThibaudinF Berthoux

❮ Previous
Next ❯

Citations

Dec 26, 2001·Transplantation Proceedings·S J WaltersJ B Chilcott
Apr 21, 2009·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Rachael L MortonJonathan C Craig
Nov 20, 2002·Expert Opinion on Pharmacotherapy·Mitchell L Henry, Amer Rajab
Dec 8, 2006·Expert Opinion on Biological Therapy·Carlo B Ramirez, Ignazio R Marino
Jun 7, 2005·Expert Opinion on Drug Safety·Ugo BoggiFranco Mosca
Dec 4, 2010·Transplantation Reviews·Juan F DelgadoCarlos S de la Calzada
Jul 14, 2010·Transplantation Proceedings·N A Neidlinger, H W Sollinger
Jan 3, 2016·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Martin HowellKirsten Howard
Apr 21, 2007·Transplantation Proceedings·M S SidhuA Sankar
Jun 15, 2006·Transplant International : Official Journal of the European Society for Organ Transplantation·Flavio VincentiNorio Yoshimura
Aug 4, 2015·Current Transplantation Reports·Alexandra James, Roslyn B Mannon
Jan 16, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Ylian S LiemM G Myriam Hunink
Jan 22, 2010·The Cochrane Database of Systematic Reviews·Angela C WebsterJonathan C Craig
Dec 11, 2003·Drugs·Therese M Chapman, Gillian M Keating
Jul 27, 2005·Pharmazie in unserer Zeit·Ingolf Griebsch
Jul 22, 2017·The Cochrane Database of Systematic Reviews·Krishna M KarpeGiles D Walters

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.